A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia

Trial Profile

A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational
  • Acronyms GREEN
  • Sponsors Roche
  • Most Recent Events

    • 06 Dec 2016 Results of exploratory analysis (n=622) assessing effectiveness presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top